Bora Pharmaceuticals Co Ltd (6472) AI Stock Analysis

Bora Pharmaceuticals Co Ltd

(TWSE:6472)

Select Model

Rating:61Neutral

Price Target:TWD 421.00▲(4.47% Upside)

Action:initiatedcoverage

Date:11/10/26

The score is supported by solid financial performance and improved cash generation, but declining revenue and profitability, elevated leverage, weak technical positioning, and a relatively high P/E ratio weigh on the outlook.

Positive Factors

Solid ProfitabilityThe company retains a solid profitability profile despite recent pressure, with gross and net margins indicating meaningful earnings power. This provides internal resources for investment, supports resilience across market conditions, and suggests the core pharmaceutical model remains economically attractive over the next several quarters.

Negative Factors

Recent Revenue ContractionThe latest revenue contraction interrupts the company’s earlier expansion and indicates that growth momentum has weakened. If this persists, slower top-line progress could limit operating leverage, reduce the capacity to absorb fixed costs, and make future earnings growth more dependent on margin recovery.

Bora Pharmaceuticals Co Ltd (6472) vs. SPDR S&P 500 ETF (SPY)

Market Cap: TWD 51.41B
Dividend Yield: 2.48%
Average Volume (3M): 840.22K
Price to Earnings (P/E): 32.7
Beta (1Y): 0.16
Revenue Growth: -5.57%
EPS Growth: -62.77%
Country: TW
Employees: 2,255
Sector: General
Sector Strength: 55
Industry: Drug Manufacturers - Specialty & Generic

Bora Pharmaceuticals Co Ltd Business Overview & Revenue Model

Company Description

Globally, Bora Pharmaceuticals Co., LTD. is engaged in the comprehensive lifecycle of pharmaceutical products, encompassing research and development, manufacturing, distribution, and sales. The organization operates through key divisions, including S...

Bora Pharmaceuticals Co Ltd Financial Statement Overview

Summary

Profitability and cash generation are solid, with healthy margins and stronger free cash flow, but declining revenue and profitability, lower return on equity, and still-elevated leverage limit the score.

Income Statement

70Positive

Balance Sheet

65Positive

Cash Flow

75Positive

Financial statement breakdown
Breakdown	TTM	Dec 2025	Dec 2024	Dec 2023	Dec 2022	Dec 2021
Income Statement
Total Revenue	19.55B	19.01B	19.25B	14.20B	10.49B	4.90B
Gross Profit	7.64B	7.66B	7.71B	6.99B	2.91B	1.67B
EBITDA	4.08B	4.23B	6.46B	5.86B	2.27B	1.29B
Net Income	1.55B	2.98B	3.94B	3.03B	1.39B	749.74M
Balance Sheet
Total Assets	52.08B	44.71B	45.60B	25.05B	22.76B	7.37B
Cash, Cash Equivalents and Short-Term Investments	8.49B	5.14B	5.92B	3.40B	3.53B	910.83M
Total Debt	21.82B	18.23B	18.98B	5.01B	7.60B	2.23B
Total Liabilities	34.54B	27.24B	30.59B	13.29B	17.62B	4.22B
Stockholders Equity	15.12B	15.38B	12.87B	9.08B	4.53B	3.15B
Cash Flow
Free Cash Flow	1.89B	3.31B	293.76M	3.18B	1.81B	873.05M
Operating Cash Flow	3.00B	4.24B	980.81M	4.61B	2.01B	1.24B
Investing Cash Flow	-3.22B	-3.45B	-10.68B	-2.46B	-4.28B	-225.85M
Financing Cash Flow	3.78B	-1.04B	12.07B	-2.44B	4.59B	-741.40M

Bora Pharmaceuticals Co Ltd Peers Comparison

Overall Rating

UnderperformOutperform

Sector (55)

Financial Indicators

TW:6472 against its peers
Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
TW:6472	61Neutral	TWD 50.12B	32.71	―	2.48%	-5.57%	-62.77%
TW:1795	57Neutral	TWD 44.28B	10.79	―	1.64%	48.98%	-21.95%
Sector *	55Neutral	$6.65B	3.83	-15.92%	6.20%	10.91%	7.18%
TW:6949	33Underperform	TWD 54.47B	-138.20	―	―	7.81%	―

* General Sector Average

Performance Comparison

TW:6472 and its peers over the selected period
Ticker	Company Name	Price	Change	% Change
TW:6472	Bora Pharmaceuticals Co Ltd	403.00	-150.21	-27.15%
TW:1795	Lotus Pharmaceutical Co., Ltd.	156.00	-130.37	-45.52%
TW:6949	PELL Bio-Med Technology Co Ltd	44.75	25.91	137.55%
TW:7799	Heron Neutron Medical Corp.	432.00	-185.00	-29.98%
TW:7924	TLC BioSciences Corp	402.50	192.00	91.21%

Glossary

BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.

Date of analysis: Nov 09, 2026

Bora Pharmaceuticals Co Ltd AI Stock Analysis